These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9864253)

  • 1. Killing of Borrelia burgdorferi by antibody elicited by OspA vaccine is inefficient in the absence of complement.
    Nowling JM; Philipp MT
    Infect Immun; 1999 Jan; 67(1):443-5. PubMed ID: 9864253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey.
    Aydintug MK; Gu Y; Philipp MT
    Infect Immun; 1994 Nov; 62(11):4929-37. PubMed ID: 7927774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Borrelia burgdorferi escape mutants that survive in the presence of antiserum to the OspA vaccine are killed when complement is also present.
    Solé M; Bantar C; Indest K; Gu Y; Ramamoorthy R; Coughlin R; Philipp MT
    Infect Immun; 1998 Jun; 66(6):2540-6. PubMed ID: 9596714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.
    de Silva AM; Telford SR; Brunet LR; Barthold SW; Fikrig E
    J Exp Med; 1996 Jan; 183(1):271-5. PubMed ID: 8551231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
    Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
    J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
    Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
    Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks.
    de Silva AM; Zeidner NS; Zhang Y; Dolan MC; Piesman J; Fikrig E
    Infect Immun; 1999 Jan; 67(1):30-5. PubMed ID: 9864192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reservoir targeted vaccine for lyme borreliosis induces a yearlong, neutralizing antibody response to OspA in white-footed mice.
    Meirelles Richer L; Aroso M; Contente-Cuomo T; Ivanova L; Gomes-Solecki M
    Clin Vaccine Immunol; 2011 Nov; 18(11):1809-16. PubMed ID: 21918116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Lyme disease after OspA vaccine.
    Schutzer SE; Luan J; Coyle PK
    N Engl J Med; 1997 Sep; 337(11):794-5. PubMed ID: 9289653
    [No Abstract]   [Full Text] [Related]  

  • 12. A Novel multivalent OspA vaccine against Lyme borreliosis is safe and immunogenic in an adult population previously infected with Borrelia burgdorferi sensu lato.
    Wressnigg N; Barrett PN; Pöllabauer EM; O'Rourke M; Portsmouth D; Schwendinger MG; Crowe BA; Livey I; Dvorak T; Schmitt B; Zeitlinger M; Kollaritsch H; Esen M; Kremsner PG; Jelinek T; Aschoff R; Weisser R; Naudts IF; Aichinger G
    Clin Vaccine Immunol; 2014 Nov; 21(11):1490-9. PubMed ID: 25185574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of OspA monoclonal antibody C3.78 with Borrelia burgdorferi within ticks.
    Gipson CL; de Silva AM
    Infect Immun; 2005 Mar; 73(3):1644-7. PubMed ID: 15731064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of OspA vaccination-induced serological correlates of protection against Lyme borreliosis in a mouse model.
    Schwendinger MG; O'Rourke M; Traweger A; Savidis-Dacho H; Pilz A; Portsmouth D; Livey I; Barrett PN; Crowe BA
    PLoS One; 2013; 8(11):e79022. PubMed ID: 24260146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi.
    Luke CJ; Carner K; Liang X; Barbour AG
    J Infect Dis; 1997 Jan; 175(1):91-7. PubMed ID: 8985201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of recombinant Bacille Calmette-Guérin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine.
    Edelman R; Palmer K; Russ KG; Secrest HP; Becker JA; Bodison SA; Perry JG; Sills AR; Barbour AG; Luke CJ; Hanson MS; Stover CK; Burlein JE; Bansal GP; Connor EM; Koenig S
    Vaccine; 1999 Feb; 17(7-8):904-14. PubMed ID: 10067697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional heterogeneity in the antibodies produced to Borrelia burgdorferi.
    Benach JL
    Wien Klin Wochenschr; 1999 Dec; 111(22-23):985-9. PubMed ID: 10666815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA.
    Koide S; Yang X; Huang X; Dunn JJ; Luft BJ
    J Mol Biol; 2005 Jul; 350(2):290-9. PubMed ID: 15935380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elimination of Borrelia burgdorferi from vector ticks feeding on OspA-immunized mice.
    Fikrig E; Telford SR; Barthold SW; Kantor FS; Spielman A; Flavell RA
    Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5418-21. PubMed ID: 1608951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.